NEW SHARE ISSUE IN SCN HAS BEEN CARRIED OUT

(NGM: SCN)

The rights issue in Scandinavian Clinical Nutrition i Sverige AB (publ) (“SCN”) has now been carried out. Through the new share issue, SCN is provided with MSEK 37 in funds before costs associated with the issue.

The new share issue will result in an increase of the number of shares by 1,232,560 shares to 16,023,284 shares when the issue is registered with the Swedish Companies Registration Office, which is planned to happen in late July, 2008.

For more information, please contact:

Thomas Christensen, CEO, tc@scnutrition.com, +47 922 55 444

Ulf Söderberg, Chairman of the Board, us@scnutrition.com, +46 708 13 22 81

Scandinavian Clinical Nutrition AB (publ) works in R&D and sales of scientifically documented products within the field of nutrition (nutraceuticals). Established in 2006, SCN maintains a product portfolio with established trademarks, such as CUUR, Coldizin, Immulina and Ledactin. Core competence and strategic alliances within both R&D and sales, in combination with innovative and scientifically documented products, create the right conditions for profitable growth on the international market. The shares of SCN are traded under the ticker “SCN” on Oslo Axess (www.osloaxess.no) and NGM Equity (www.ngm.se).